'Portal hypertension in MASLD and how to measure it' presented at the #SLDSummit in Prague: Thomas Reiberger (AT). Take Home Message: PH in MASLD. 1. Steatosis & endothelial dysfunction in MASLD affect PH severity. 2. HVPG seems to underestimate "true" PP in MASLD, thus, MASLD

@JVLazarus @EASLnews @AleksanderKrag @schattenbergJ @brennap9 @aelsharkawy75 @ProfJohnDillon @ArunJSanyalVCU @NoureddinMD @capicchio @AASLDPresident @JHepatology @AlkhouriNaim @phil_newsome7 @Aurorabbelles @ajay_duseja @ebtapper @FrancqueSven @CUNYSPH @ISGLOBALorg @DrJavierCrespo @AEEHLiver @INASL_Liver @DrLoomba @IanARowe @marurinella @MajaThiele @mcharltonmd @IsraelsenMads @Camilla_Dalby @FattyLiverA @JonathanStineMD @WHO @alehlatam @HEP_Journal @GCastro_NarroMD @PIruzubieta @pericas_jm @shivaramsingh @DebbieShawcros1 @HenryEMark @docfromtheblock @MikkelsenBente_ @DrJLCalleja @QAnstee MASLD as a vascular disease has been a recurring theme at #SLDsummit. Great review on these data by @RautouE and that of the role of platelets on pathogenesis by @FrancqueSven

The 2025 EASL #SLDsummit content is now available on demand is now accessible on demand for all users with a MyEASL account. Re-discover the sessions and ePosters on EASL Campus!. 🔗 #LiverX #LiverTwitter

'Metabolic risk factors and alcohol: current data and future avenues of research and clinical practice' with Aleksander Krag (DK) #SLDSummit. Take aways:. *  New nomenclature is operational. *  SLD and its most common subclasses portend distinct prognoses. *  Prognosis worsen

📢 MASLD and the ❤️system #SLDSummit 2023!.•🎯 How vascular lesions contribute to #MASLD/MASH.•💊Statins & platelet-interacting meds show promise.•🩸Endothelium: A key player in MASLD pathogenesis.•🌐MASLD as a multisystem disease. @EASLedu @aelsharkawy75 @AleksanderKrag

'Clinical outcome trials', presented by: Elisabetta Bugianesi (IT) at #SLDSummit . "Clinical Benefit: How do we define it?.A positive clinically meaningful effect of an intervention, i.e. a positive effect on:.-  How long a patient lives.-  How a patient feels or functions in

'NITs and prognosis in MASLD' with an excellent presentation by: @AlinaAllenMD (US) #SLDSummit. "ELF works quite well in the general population". "Not all cirrhosis is the same". "Combining liver stiffness with a biomarker. has been studied". *  There are consistent data

📢 Jacob George delves into #MASLD & ❤️ Disease at #SLDSummit 2023!.🔄 Liver is at the center of a complex web with other systems.❤️ events: Leading cause of death in MASLD patients.🎯 Future trials must adapt for this complexity.@JVLazarus @EASLedu @EuropeLiver @AleksanderKrag

The importance of Lipid Droplets size 🟡 presented at #SLDSummit . A passionate session with clinically relevant discussion. Thanks for the opportunity to share our study.@EASLnews @EASLedu and for the travel award ✈️ @Biomed_MDPI . @incliva_iis @GVAclinic @GIBI230 @DigestivoHCV

The first #SLD meeting has begun in Prague with an exciting agenda! Looking forward to learning and discussions .#SLDsummit #livertwitter

'Methodological limitations of NITs presented' by: Jerome Boursier (FR) #SLDSummit. - What if biopsy and NIT results differ? Biopsy correct 1/3, 1/3 NIT is right, 1/3 undetermined based upon research done. - monitoring over time, biopsy errors occur. Need to continue assessing

الحمدلله تم قبول بحثي في مؤتمر أمراض الكبد الدهني ومتحمسة لعرض نتائج احدى أبحاث الدكتوراة. 📢 I’ve got wonderful news to share! 🏆 My abstract was accepted for the #EASL #SLDsummit 2023! Looking forward to sharing my research 🧪🔬🩺in Prague, from 21-23 Sept.

Summarizing our great participation at the #SLDsummit in beautiful Prague. I’m proud of Radka and Sharleen, who successfully presented their research, showcasing novel pathways/targets to modulate liver homeostasis.

Women faculty #SLDSummit once again together in #Praha! @EASLnews @my_ueg #WomeninGI @ESP_Pathology @uoaofficial @EASLedu @newcastle

🚨Clinic & Trials Challenges #SLDSummit 2023!.🔹🆕 MetALD: defining🍷cut-offs .🔹⚖️ Placebo📈: standardization .🔹🩺 Cirrhosis: Design hurdles .🔹🌡️ Portal Hypertension: MASLD-specific features.🔬 Rethink #MASH trials!. @DebbieShawcros1 @AleksanderKrag @rabataller @aelsharkawy75

🧫 Vascular lesions in MASLD .🎤@kvvanten .🐁Evidence of vascular dysfunction in rodents.🔬inflammation, oxidative stress, lipotoxicity.Affects micro/macrovascular beds.🩺 Clinical translatability?.#SLDSummit 2023! @FrancqueSven @JVLazarus @EASLedu @EuropeLiver @lotersztajn

📣 Exciting updates from the #SLDSummit! 🌍.Meet the ELPA Team at the forefront of liver health advocacy:.👨‍⚕️ Prof. Dr. Gamal Shiha M.D. - ELPA Director.🇪🇺 Veronika Všetíčková - Head of EU Affairs.🔬 Dr. Helena Glasoova - ELPA Scientific Committee member #LiverCancerAwarenessMonth

Great days at #SLDsummit in Prague - now we thank the 🤩⭐️faculty for their contributions 🙏 off to faculty dinner and the traditional female only photo 👍

Macrophages and MASLD. Great talk by @KC_DC_01 !.#SLDSummit @EASLnews

Last but not least at #SLDSummit @EASLnews @EASLedu. Public Health Session with @LuisAntonioDiaz showing the magnitud of #MASLD policies and the prevalence of cirrosis and HCC. Congratulations for this impactful study 👏👏